The first ever joint clinical assessment (JCA) report, on Ipsen’s rare cancer drug Ojemda (tovorafenib), leaves room for improvement for ensuring that EU-level JCAs carried out under the Health Technology Assessment Regulation are suitable for orphan drugs, according to Matias Olsen of the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE).
And given that Ipsen was only able to respond to one of eight key questions with data, more needs to...



